Chidozie Ugwumba Sells 4,015 Shares of Clene (NASDAQ:CLNN) Stock

Posted by Paula Ricardo on Jan 2nd, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 4,015 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $5.73, for a total value of $23,005.95. Following the sale, the insider owned 766,480 shares in the company, valued at approximately $4,391,930.40. This trade represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total transaction of $76,081.95.
On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The stock was sold at an average price of $6.03, for a total transaction of $24,952.14.
On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The shares were sold at an average price of $5.95, for a total transaction of $48,171.20.
On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $42,830.37.
On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The stock was sold at an average price of $6.32, for a total transaction of $21,172.00.
On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $9,342.30.
On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total value of $28,560.18.
On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The shares were sold at an average price of $6.45, for a total value of $36,003.90.
On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total transaction of $36,815.28.

Clene Stock Performance

Shares of NASDAQ CLNN traded down $0.10 during midday trading on Friday, reaching $5.77. The stock had a trading volume of 53,787 shares, compared to its average volume of 142,077. The company’s 50 day moving average price is $8.11 and its 200 day moving average price is $6.33. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50. The firm has a market cap of $59.60 million, a price-to-earnings ratio of -1.70 and a beta of 0.88.

Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Equities analysts forecast that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of Clene in a research note on Wednesday, December 10th. UBS Group restated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. Finally, Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Clene currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Read Our Latest Research Report on Clene

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CLNN. Scoggin Management LP raised its position in Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the last quarter. Lunt Capital Management Inc. lifted its position in shares of Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after purchasing an additional 1,250 shares in the last quarter. Jane Street Group LLC purchased a new position in Clene during the second quarter worth about $47,000. Finally, Jones Financial Companies Lllp bought a new stake in Clene in the 3rd quarter worth about $29,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).